For many people, the first fertility treatment they ever hear about is a pill or an injection that makes an ovary release an egg. It sounds almost simple: take a medication, time things correctly, and hope. Ovulation induction is exactly that idea made precise — the use of medication to make the ovaries mature and release an egg in a controlled, observable way. It is one of the oldest and most widely used tools in reproductive medicine, and for the right patient it can be both effective and low-burden.
This guide explains what ovulation induction is, who it is for, how the oral medications and injectable gonadotropins actually work, how a cycle is monitored, how the trigger shot and timing are handled, what the realistic success figures mean, and how the two main risks — multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) — are managed. It is written for patients in Torrance and the South Bay who want to understand the reasoning behind a plan their clinic has proposed. Every statistic here is a population-level figure from published research and professional guidance — not a prediction about your body, your cycle, or your outcome, and not a clinic-specific result or promise.
1. What Ovulation Induction Actually Is — and Who It Is For
Ovulation induction is the use of medication to stimulate the ovaries to mature and release one or more eggs. In a natural cycle, the pituitary gland releases follicle-stimulating hormone (FSH), which makes one dominant follicle grow; that follicle produces estrogen, and a later surge of luteinizing hormone (LH) triggers the egg’s release. Induction medicines work by changing that hormonal conversation — either by making the brain perceive lower estrogen (so it releases more FSH), or by supplying FSH directly.
ASRM’s patient guidance describes two main reasons to induce ovulation. The first is when a person does not ovulate regularly or at all — the medicine helps the ovary mature and release an egg. The second is when a person ovulates on their own but has not conceived; in that setting, medication may be used to release more than one egg as part of a fertility treatment such as intrauterine insemination (IUI). Your clinic determines which situation applies to you.
It is worth being precise about a term that is often blurred. In IVF, the same drugs are used for a different purpose — controlled ovarian stimulation to produce many eggs for retrieval — which is covered in our guides to egg retrieval and the IVF journey. In this article, “ovulation induction” means the goal of a single mature follicle, used with timed intercourse or IUI — not the multi-egg stimulation of IVF.
2. First, Confirm the Diagnosis Before Treating
Induction is only sensible once the reason for not conceiving is understood. Irregular or absent ovulation is common — it is a core feature of PCOS (now also called PMOS) — but it is not the only cause, and a medication that helps one person may be useless or inappropriate for another.
A basic evaluation usually confirms whether ovulation is happening, checks ovarian reserve with AMH and related tests, assesses the uterine cavity and fallopian tubes, and includes a semen analysis for the male partner. Our guide to fertility testing and the infertility workup walks through these steps in detail. Ovulation itself can be tracked at home with urine LH kits, a menstrual calendar, or cycle apps — each with limits — and confirmed in the clinic with ultrasound and blood tests.
This step matters because ovulation induction cannot fix everything. If the tubes are blocked or sperm counts are very low, inducing ovulation alone will not overcome those barriers, and the plan may reasonably move toward IUI or IVF. A clinic that recommends medication before a basic workup deserves a question about why.
3. The Goal: One Mature Follicle, Not Many
This is the single most important concept in ovulation induction, and the one patients most often miss. ASRM’s committee opinion states the goal plainly: to promote the development of a single mature follicle. Monofollicular development lowers the risk of multiple gestation and OHSS, while multiple follicles raise both risks substantially. “More follicles” is not the same as “better” in an induction cycle.
That is why induction is a careful balancing act. The medicine is started at a low dose and increased cautiously, and the cycle is watched closely with ultrasound and blood tests. If too many follicles develop, the safest decision is often to cancel the cycle, or — in IVF — to convert to a different strategy. A canceled cycle is a disappointment, but it is a deliberate safety choice, not a failure of care.
4. Oral Medications: Letrozole and Clomiphene Citrate
Most people start with an oral medication because it is simple, inexpensive, and well tolerated. The two most commonly used are clomiphene citrate (often called CC or by the brand name Clomid) and letrozole, which belongs to a class called aromatase inhibitors.
They work in slightly different ways. According to ASRM’s patient fact sheet on oral medicines for inducing ovulation, clomiphene makes cells “resist” estrogen — the brain reads this as low estrogen and responds by producing more FSH, which helps a follicle grow. Aromatase inhibitors such as letrozole block the conversion of androgens into estrogen, similarly lowering estrogen levels and prompting the pituitary to release FSH. In both cases, the final common pathway is the same: more FSH, a growing follicle, and ovulation.
Letrozole is not formally approved by the FDA for ovulation induction, but it is widely used off-label and ASRM describes it as an effective and well-tolerated option; in PCOS, recent studies suggest pregnancy rates similar to clomiphene. Neither drug should be taken by someone who is already pregnant. Reported side effects can include mood changes, hot flashes, and — with clomiphene — visual disturbances, which are a reason to stop and contact the care team. Ovarian cysts can occur but usually resolve on their own.
Timing and dose are individualized; do not copy a friend’s schedule. Your clinic decides how many days to take the medication and at what dose based on your diagnosis and response.
5. Metformin and Insulin-Sensitizing Agents
A third category of oral medication is the insulin-sensitizing agents, of which metformin is the best known. These do not stimulate the ovary directly. Instead, they improve how the body uses insulin, which can lower high insulin and androgen levels that interfere with ovulation — particularly in people with PCOS, where insulin resistance is common.
ASRM notes that insulin-sensitizing agents may be used alongside clomiphene or an aromatase inhibitor, and are sometimes used in people found to have pre-diabetes. They may be considered when metabolic factors are part of the picture. They add little to the risk of multiple pregnancy. This is one reason our guides on nutrition, weight, and lifestyle for fertility and PCOS so often overlap with medication discussions — the metabolic and the hormonal are linked.
Metformin is not a quick fix and is not a substitute for ovulation induction in everyone. Its role is best decided as part of a full assessment that includes metabolic screening.
6. Injectable Gonadotropins — When Oral Agents Are Not Enough
When oral medications do not produce ovulation or pregnancy, the next step is often injectable gonadotropins — medications that contain FSH, LH activity, or both. Forms include human menopausal gonadotropin (hMG), purified or recombinant FSH, and hCG, used alone or in combination.
Gonadotropins are more potent and more expensive than oral agents, and they require far closer monitoring because they can drive multiple follicles and carry a higher risk of OHSS and multiple pregnancy. ASRM recommends that they be started at a low dose — 37.5 to 75 IU per day — and increased cautiously to achieve monofollicular development, and that they be managed by a clinician with the appropriate training and experience.
For people with hypothalamic amenorrhea — where the brain does not signal the ovaries adequately — gonadotropins can be an especially important tool, because these patients often lack the endogenous hormones needed to respond to oral agents. A 2020 ASRM committee opinion notes pregnancy rates of about 15% per cycle and 41% per patient over an average of 2.7 cycles in anovulatory women treated with gonadotropins, and about 25% per cycle in a small study of women with hypothalamic amenorrhea. These are group figures, not individual forecasts.
7. What a Cycle Looks Like, Step by Step
Although every protocol is individualized, a typical induction cycle follows a recognizable sequence. Oral medications such as letrozole or clomiphene are usually taken for a short window early in the cycle — often beginning around day 2 to 5 — after which monitoring begins. Injectable gonadotropins are started at a low daily dose early in the cycle and adjusted based on response.
For stimulation in general, published ASRM patient material describes roughly 8 to 14 days of medication before the follicles are ready — a timeframe that overlaps with the early stimulation phase of IVF described in our egg retrieval guide. In an induction cycle, the aim is fewer, carefully watched follicles rather than many. Throughout, you will have ultrasound scans and blood tests, and your dose may be adjusted — or the cycle may be paused — depending on what those show.
It helps to think of the cycle as a conversation: the medication pushes, the monitoring listens, and the clinical team adjusts the plan in response. Patients who keep a simple record of scan dates, doses, and symptoms usually find appointments more productive.
8. Monitoring With Ultrasound and Estradiol
Monitoring is what makes induction safe rather than guesswork. ASRM’s gonadotropin guidance states that safety and efficacy depend on careful monitoring with serial transvaginal ultrasonography and estradiol measurements. Ultrasound provides a structural picture of follicle development; estradiol, measured in blood, provides a functional gauge of how the ovaries are responding.
Ultrasound generally begins after the first 4 to 5 days of treatment and then repeats at intervals of 1 to 3 days, depending on response. The team looks at the number and size of follicles, and often at endometrial thickness and pattern as an indirect sign of how the lining is developing. Estradiol levels are interpreted together with the scan — a high level alongside several growing follicles changes the plan.
ASRM emphasizes that follicles as small as 10 to 12 mm at the time of ovulation can contribute to multiple-gestation risk, which is why intermediate-sized follicles matter, not only the largest one. This is also where cycle cancellation criteria come in: ASRM suggests considering cancellation when more than two follicles exceed 16 mm, or when three or more intermediate-sized follicles develop. Home ovulation kits can help time events but do not replace this monitoring.
9. The Trigger Shot and Timing Ovulation
When the follicle is mature, a “trigger” injection can be given to bring on final maturation and release. ASRM describes the usual hCG trigger as 5,000 to 10,000 IU of urinary hCG, or about 250 micrograms of recombinant hCG (roughly equivalent to 6,000 to 7,000 IU of urinary hCG). Ovulation is expected about 36 to 48 hours after the trigger.
That window is why timing is everything. Intercourse or IUI is scheduled to occur just before ovulation, when the egg is about to be released. In a natural or minimally assisted cycle, a person may rely on an LH surge detected at home; with a trigger shot, the timing is controlled and predictable. Your clinic will give exact instructions — the timing of a trigger is not something to approximate.
A GnRH agonist can also be used as a trigger in selected patients, particularly those at high risk of OHSS, because it produces a shorter hormonal effect. ASRM notes it should not be used in patients with hypogonadotropic hypogonadism, who often lack the stored LH needed to respond. This is a specialist decision, not a general rule.
10. Timed Intercourse or IUI: Pairing Induction With a Delivery Method
Induction creates the egg; a separate decision determines how sperm reaches it. The two common pairings are timed intercourse and intrauterine insemination (IUI), in which washed, concentrated sperm are placed directly into the uterus around ovulation.
ASRM’s guideline on unexplained infertility is clear on this point: clomiphene citrate with IUI is recommended, letrozole with IUI can be considered as an alternative, and using these oral drugs with timed intercourse alone is not recommended for unexplained infertility because it is no more effective than expectant management. That does not make timed intercourse wrong for everyone — in anovulatory patients, restoring ovulation itself can be the treatment — but it explains why a clinic may steer toward IUI when no clear cause has been found.
The choice also depends on male factor. If sperm parameters are borderline, IUI can help; if they are severely abnormal, the conversation shifts toward IVF with or without ICSI. Our comparison of IUI versus IVF covers how these paths are weighed, and age is a major factor in how long it is reasonable to try less intensive treatment before moving on.
11. Luteal Support After Ovulation
After ovulation, the ruptured follicle becomes the corpus luteum and produces progesterone, which prepares and maintains the uterine lining for a possible pregnancy. Some induction cycles — especially those using gonadotropins — can leave the luteal phase inadequate, and a systematic review cited by ASRM found a higher live-birth rate with progesterone luteal support after ovulation induction and IUI in women with unexplained infertility.
ASRM’s gonadotropin committee opinion states that luteal support is beneficial following gonadotropin induction in women with hypothalamic amenorrhea, and that it may also be beneficial in women with PCOS/PMOS, though evidence is insufficient for a firm recommendation there. In practice, your clinic will decide whether progesterone support is part of your plan based on your diagnosis and how the cycle unfolded.
If a pregnancy does occur, the first weeks bring their own questions. A follow-up blood test confirms it, and early bleeding or loss can be alarming — our guide to recurrent pregnancy loss addresses evaluations when losses repeat. The emotional side of waiting is real, and fertility-focused emotional support can help.
12. How Success Is Measured — Honestly
Success figures for ovulation induction are easy to quote and easy to misread. Always ask what the denominator is: ovulation rate per cycle, clinical pregnancy per cycle, pregnancy per patient over several cycles, or live birth. These are different numbers, and a clinic that reports only the most flattering one is not being transparent.
The figures that appear in this guide come from published research, not from Incinta Fertility. ASRM’s committee opinion reports about 15% pregnancy per cycle and 41% per patient over an average of 2.7 cycles with gonadotropins in anovulatory women; the ASRM oral-medicines fact sheet reports a twin risk of 5% to 8% with clomiphene or aromatase inhibitors. Your own chances depend on your age, diagnosis, ovarian reserve, sperm factors, and how you respond — variables no population average can capture.
We deliberately do not publish clinic-specific “success rates” in these guides, because a single percentage cannot carry the nuance your case deserves. The useful conversation is with your physician, using your own test results and a written plan.
13. Risks and How They Are Managed
Two risks dominate discussions of ovulation induction: multiple gestation and OHSS. Both are related to the number of follicles that develop, which is why the entire strategy of monitoring and low-dose escalation is aimed at keeping that number low.
Multiple pregnancy. ASRM’s patient fact sheet reports a twin chance of 5% to 8% with clomiphene or aromatase inhibitors, with triplets or higher-order multiples under 1%. With injectable gonadotropins, the risk is higher — ASRM notes multiple gestation as high as 36% when strict cancellation criteria are not used, and emphasizes that cancellation criteria dramatically reduce this. Twin and higher-order pregnancies carry real medical and financial implications, which is why a singleton pregnancy is the usual goal.
OHSS. This is a condition in which the ovaries over-respond and fluid shifts into the abdomen and other spaces. It is far more common with injectable gonadotropins and in people with PCOS or a high ovarian reserve, and is unusual with oral agents. ASRM states the risk cannot be completely eliminated, even with strict criteria. Our dedicated guide to OHSS — risk factors, prevention, and warning signs covers the symptoms that require urgent attention. Patients with low ovarian reserve are at low risk; those with PCOS or a high response need closer watch.
Other considerations. Ovarian cysts may occur but usually resolve; ASRM reports no established link between these medicines and ovarian cancer and no known increase in birth defects. Still, these drugs are prescription medications with real effects, and they should be used under medical supervision.
14. Special Situations: PCOS, Hypothalamic Amenorrhea, Unexplained Infertility, and Low Reserve
The same medication can play a different role depending on the diagnosis. In PCOS/PMOS, where ovulation is irregular but reserve is often high, oral agents are typically first-line and the main caution is over-response — too many follicles, OHSS, and multiples. Weight and metabolic health are part of treatment. In hypothalamic amenorrhea, where the brain’s signaling is the problem, injectable gonadotropins may be needed because oral agents depend on a pituitary response that may be blunted.
In unexplained infertility, ASRM recommends against gonadotropins with timed intercourse and suggests oral agents with IUI instead, because higher-dose gonadotropin regimens raise multiple-gestation risk without a clearly proportional benefit. Our guides to secondary infertility and fertility testing show how a changing diagnosis can change the plan.
In diminished ovarian reserve or premature ovarian insufficiency, the issue is egg supply rather than ovulation signaling. Stimulation may yield few or no eggs, and time is a more pressing factor; induction alone is often not the answer, and a discussion about IVF or other options may come sooner. Age changes this calculus across the board, as outlined in our guide to age and fertility.
15. Frequently Asked Questions
Is ovulation induction the same as IVF?
No. Induction aims to mature and release one or a few eggs for timed intercourse or IUI, with fertilization happening inside the body. IVF uses stimulation to collect multiple eggs, fertilizes them in a lab, and transfers embryos. See our IUI versus IVF guide.
Can I take letrozole or clomiphene on my own?
They are prescription medications and should be used under medical supervision with monitoring. Dosing, timing, and appropriateness depend on your diagnosis, and these drugs should not be taken if you are already pregnant.
How will I know if I am ovulating?
Home LH kits can suggest a surge, but hormone patterns can be misleading. Ultrasound and blood estradiol/progesterone measurements in the clinic give a clearer picture, which is why monitoring is part of treatment.
What are the chances of twins?
ASRM reports about 5% to 8% with clomiphene or aromatase inhibitors and under 1% for triplets or more; the risk is higher with injectable gonadotropins. Careful monitoring and cancellation criteria are used to keep this risk low.
What is the trigger shot and does it hurt?
It is an injection of hCG (or occasionally a GnRH agonist) that causes final egg maturation; ovulation follows in roughly 36 to 48 hours. It is a small injection, and your clinic will give exact timing instructions.
What if too many follicles develop?
The cycle may be canceled to reduce the risk of multiples and OHSS, or your dose may be adjusted. Cancellation is a safety decision, and the team will discuss the plan for a future cycle.
How many cycles should I try?
This depends on your diagnosis, age, and response. ASRM patient material notes that if clomiphene or letrozole do not induce ovulation, or if pregnancy does not occur within about six ovulatory cycles, gonadotropins or other treatments may be considered. Your physician will set a timeline with you.
Medical and informational disclaimer: This article is general educational information, not medical advice, and it is not a substitute for evaluation by a qualified reproductive endocrinology specialist. Any statistics, percentages, or ranges mentioned are population-level figures from published research, guidelines, and authoritative sources (such as ASRM, NICHD, MedlinePlus, and professional society guidance); they are typical ranges for groups, not predictions about any individual, and they are not clinic-specific results, guarantees, or quotes. Whether to pursue ovulation induction, which medication to use, all doses, monitoring, and costs should be discussed directly with your medical team in a written, individualized assessment before any decision.
Incinta Fertility Center — Fertility Clinic Torrance & South Bay, California
By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team